Table S3a. Reported rates of adverse events of special interest

Citation	CRS, %		ICANS, %		Infection, %		Fever/pyrexia, %		Fatigue, %	
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Viardot et al., 2016[29]	0	0	NR	NR	NR	NR	43.5	4.3	26.1	0
Gaballa et al., 2023[30]	48	0	27	9.7	NR	NR	NR	NR	NR	NR
Hawkes et al., 2022[31, 51]	0	0	0	0	NR	NR	NR	NR	25	0
Bannerji et al., 2022[32]	61	7	12	3	49	23	73	1	33	5
Melchardt et al., 2023[33]	30	0	0	0	60	20	NR	NR	NR	NR
Hutchings et al., 2019[34]	42	0	NR	NR	NR	NR	37	NR	24	NR
Hutchings et al., 2023[35]	58.3	1.3	NR	NR	NR	NR	16.7	NR	17.9	NR
Dickinson et al., 2022[36]	63	3.9	8	3	38	15	18.2	0	11.7	0.6
Falchi et al., 2023[37]	60	2	2.1	0	NR	NR	40	NR	40	NR
Vermaat et al., 2023[38]	43	4	0	0	NR	NR	NR	NR	25	NR
Brody et al., 2023[39]	56	3	2.9	0	NR	NR	NR	NR	NR	NR
Abrisqueta et al., 2022[40]	41	0	3.4	0	NR	NR	NR	NR	28	NR
Thieblemont et al., 2023[41]	49.7	2.5	6.4	0.6	45.2	14.6	23.6	0	22.9	1.9
Vose et al., 2023[42]	17	0	0	0	38	NR	NR	NR	21	NR
Patel et al., 2022[43]	72.2	0	NR	NR	NR	NR	38.9	NR	NR	NR
Song et al., 2023[44]	12.8	0	0	0	NR	NR	NR	NR	NR	NR
Olszewski et al., 2023[45]	60	0	12.5	2.5	52.5	22.5	20	0	47.5	10
Matasar et al., 2024[46]	39.4	2.8	0.9	0	46.8	15.1	24.3	1.8	32.1	0.9
Budde et al., 2024[47]	16.7	2.5	4.9	1.6	39.2	10.8	20	NR	46.7	6.7

Abbreviations: CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; NR, not reported

Table S3b. Reported rates of cytopenias

Citation	Anemia, %		Thrombocytopenia, %		Neutropenia, %		Leukopenia, %		Lymphopenia, %	
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Viardot et al., 2016[29]	4.4*	NR	21.7	17.4	4.4	NR	17.4	17.4	NR	NR
Gaballa et al., 2023[30]	34	0	NR	NR	32	NR	20.9	NR	29	NR
Hawkes et al., 2022[31, 51]	31	6	25	13	19	19	NR	NR	NR	NR
Bannerji et al., 2022[32]	38	25	28	14	25	19	19	9	22	19
Melchardt et al., 2023[33]	10	0	NR	NR	NR	NR	NR	NR	NR	NR
Hutchings et al., 2019[34]	29	13	NR	NR	21	18	NR	NR	NR	NR
Hutchings et al., 2023[35]	22.5	NR	NR	NR	28.6	NR	NR	NR	NR	NR
Dickinson et al., 2022[36]	31	6	25	8	38	27	NR	NR	NR	3.2
Falchi et al., 2023[37]	62	NR	NR	NR	64	NR	NR	NR	NR	NR
Vermaat et al., 2023[38]	21	NR	NR	NR	32	NR	NR	NR	NR	NR
Brody et al., 2023[39]	56	NR	68	NR	56	NR	NR	NR	NR	NR
Abrisqueta et al., 2022[40]	45	NR	69	NR	41	NR	NR	NR	NR	NR
Thieblemont et al., 2023[41]	17.8	10.2	13.4	5.7	21.7	14.6	NR	NR	NR	NR
Vose et al., 2023[42]	13	NR	13	NR	13	NR	NR	NR	NR	NR
Patel et al., 2022[43]	44.5	19.4	NR	11.1	NR	16.7	NR	NR	NR	NR
Song et al., 2023[44]	NR	NR	NR	NR	31.9	17	NR	NR	NR	NR
Olszewski et al., 2023[45]	42.5	30	25	17.5	70	65	10	7.5	12.5	10
Matasar et al., 2024[46]	15.1	8.3	11.5	6.9	27.5	24.3	NR	NR	NR	NR
Budde et al., 2024[47]	12.5	NR	3.3	NR	35	25	5	NR	4.2	NR

*Data taken from ClinicalTrials.gov Abbreviations: NR, not reported

Table S3c. Other frequently reported adverse events

Citation	Any grade, occurring in >20% of participants		Grade ≥3, occurring in >5% of participants	
	Adverse event	**Rate, %**	**Adverse event**	**Rate, %**
Viardot et al., 2016[29]	Tremor	47.8	Device-related infection	13
	Oedema	26.1	Pneumonia	13
	Device-related infection	21.7	C-reactive protein (CRP) increased	13
	Pneumonia	21.7	Encephalopathy	8.7
	Diarrhea	21.7	Aphasia	8.7
			Hyperglycemia	8.7
Gaballa et al., 2023[30]	N/A	N/A	NR	NR
Hawkes et al., 2022[31, 51]	Headache	25	Fall	6
	Abdominal pain	25		
	COVID-19	25		
Bannerji et al., 2022[32]	Chills	47	Hypophosphatemia	19
	Hypophosphatemia	29	Aspartate transaminase increased	10
	C-reactive protein (CRP) increased	28	Pneumonia	9
	Cough	28	Hypotension	8
	Hypotension	28	Alanine transaminase increased	7
	Headache	25	Hypoxia	6
	Nausea	24	Hyperglycemia	6
	Infusion-related reaction	24		
	Decreased appetite	23		
	Dyspnea	22		
	Blood creatinine increased	21		
	Tachycardia	21		
	Oedema peripheral	21		
Melchardt et al., 2023[33]	N/A	N/A	Bleeding	10
			Renal toxicity	10
Hutchings et al., 2019[34]	Diarrhea	21	NR	NR
	Decreased appetite	21		
Hutchings et al., 2023[35]	COVID-19	25	NR	NR
Dickinson et al., 2022[36]	N/A	N/A	Hypophosphatemia	5.8
Falchi et al., 2023[37]	NR	NR	NR	NR
Vermaat et al., 2023[38]	Constipation	21	NR	NR
	Hypokalemia	21		
Brody et al., 2023[39]	Diarrhea	59	NR	NR
	COVID-19	32		
Abrisqueta et al., 2022[40]	Nausea	34	NR	NR
Thieblemont et al., 2023[41]	Injection site reactions	28	NR	NR
	Diarrhea	20.4		

Vose et al., 2023[42]	N/A	N/A	NR	NR
Patel et al., 2022[43]	Nausea Asthenia Diarrhea Hypophosphatemia Aspartate transaminase increased	38.9 27.8 25 25 25	NR	NR
Song et al., 2023[44]	COVID-19 infection	40.4	COVID-19 infection	12.8
Olszewski et al., 2023[45]	Nausea Decreased appetite Constipation Peripheral neuropathy Diarrhea Hypokalemia Vomit Alopecia Headache Dizziness Hypotension	55 37.5 37.5 32.5 32.5 32.5 30 30 25 25 22.5	Febrile neutropenia Pneumonia Hypokalemia Decreased appetite	20 7.5 7.5 7.5
Matasar et al., 2024[46]	Hypophosphatemia Headache	22.5 20.2	Hypophosphatemia	14.7
Budde et al., 2024[47]	Diarrhea Peripheral neuropathy Nausea Decreased appetite Headache	30.8 30.8 30 22.5 21.7	N/A	N/A

Abbreviations: N/A, not applicable; NR, not reported

Table S3d. Reported efficacy outcomes

Citation	n (cohort)	MFU, months	ORR, %	CRR, %	PRR, %	mDoR, months	mPFS, months	Response criteria
				Front-line				
Melchardt et al., 2023[33]	NR	NR	NR	NR	NR	NR	NR	NR
Falchi et al., 2023[37]	n = 46	11.5	100	76	NR	Not reached	Not reached	Lugano
Vermaat et al., 2023[38]	n = 20	NR	100	85	NR	NR	NR	Lugano
Olszewski et al., 2023[45]	n = 40	32	95	90	5	Not reached	NR	Lugano
				Relapsed/refractory				
Viardot et al., 2016[29]	n = 20 (cohort I + III)	15	40	20	20	11.6	3.7	Cheson
Gaballa et al., 2023[30]	NR	NR	NR	NR	NR	NR	NR	NR
Hawkes et al., 2022[31]	n = 9 (DLBCL, combination arm)	NR	56	0	56	NR	NR	NR
Bannerji et al., 2022[32]	n = 49 (DLBCL, CAR T naïve)/ n = 33 (DLCBL, CAR T exposed)	4.2	39 / 33	24 / 24	14 / 9	4.4 / not reached	11.5 / 2	Lugano
Hutchings et al., 2019[34]	n = 31 (aNHL patients)	NR	29	9.7	NR	NR	NR	Lugano
Hutchings et al., 2023[35]	n = 57 (aNHL patients)	NR	70	53	NR	NR	NR	Lugano
Dickinson et al., 2022[36]	n = 155	12.6	52	39	NR	18.4	4.9	Lugano
Brody et al., 2023[39]	n = 34	NR	91	59	NR	NR	NR	Lugano
Abrisqueta et al., 2022[40]	n = 15 (received epcoritamab + R-DHAX/C)	9.2	100	80	20	Not reached	NR	Lugano
Thieblemont et al., 2023[41]	n = 157	10.7	63.1	38.9	24.2	12	4.4	Lugano
Vose et al., 2023[42]	NR	NR	NR	NR	NR	NR	NR	NR
Patel et al., 2022[43]	n = 19 (DLBCL patients)	NR	47.4	26.3	NR	NR	NR	NR
Song et al., 2023[44]	n = 22 (dosed at ≥3mg GB261)	4.5	73	45.5	NR	Not reached	NR	Lugano & LYRIC 2016

Matasar et al., 2024[46, 52]	n = 129	11.9	34.9	19.4	15.5	NR	NR	Cheson
Budde et al., 2024[47]	n = 98 (dose expansion)	23.9	59.2	45.9	NR	20.8	11.4	Lugano

Abbreviations: n, number (of participants); MFU, median follow-up; ORR, overall response rate; CRR, complete response rate; PRR, partial response rate; mDoR, median duration of response; mPFS, median progression free survival; NR, not reported; DLBCL, diffuse large B-cell lymphoma; CAR, chimeric antigen receptor; aNHL, aggressive non-Hodgkin's lymphoma; R-DHAX/C, rituximab/dexamethasone/cytarabine/oxaliplatin or carboplatin

References

29. Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410-6.

30. Gaballa S, Nair R, Jacobs RW, Devata S, Cho SG, Stevens DA, et al. Double step-up dosing (2SUD) regimen mitigates severe ICANS and CRS while maintaining high efficacy in subjects with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) treated with AZD0486, a novel CD19xCD3 T-cell engager (TCE): Updated safety and efficacy data from the ongoing first-in-human (FIH) phase 1 trial. Blood. 2023;142(Supplement 1):1662.

31. Hawkes E, Lewis KL, Wong Doo N, Patil SS, Miskin HP, Sportelli P, et al. First-in-human (FIH) study of the fully-human kappa-lambda CD19/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma. Blood. 2022;140(Supplement 1):6599-601.

51. Hawkes E, Lewis K, WongDoo N, Patil S, Miskin H, Sportelli P, et al. First-in-human (FIH) study of the fully-human kappa-lambda CD19/CD47 bispecific antibody TG-1801 in patients (pts) with B cell lymphoma: Poster session presented at: American Society of Hematology 64th Congress; 2022 Dec 11; New Orleans, LA.

32. Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematology. 2022;9(5):e327-e39.

33. Melchardt T, Wurm-Kuczera RI, Altmann B, Pichler P, Orlinger M, Panny M, et al. Feasibility and safety of the first-in-human chemotherapy-light combination of rituximab, polatuzumab vedotin and glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 uears of age ineligible for a fully dosed R-CHOP - R-Pola-Glo/Ikf-t062, a study of the Austrian Group for Medical Tumor Therapy (AGMT-NHL-16) and the German Lymphoma Alliance (GLA2022-10). Blood. 2023;142(Supplement 1):1734.

34. Hutchings M, Gritti G, Sureda A, Terol MJ, Dyer MJS, Iacoboni G, et al. CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-hodgkin lymphoma. Blood Conference: 61st Annual Meeting of the American Society of Hematology, ASH. 2019;134(Supplement 1).

35. Hutchings M, Dickinson M, Carlo-Stella C, Morschhauser F, Bosch F, Gritti G, et al. Combining CD19-4-1BBL (RO7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma. Hematological Oncology. 2023;41(S2):136-8.

36. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 2022;387(24):2220-31.

37. Falchi L, Clausen MR, Offner F, de Vos S, Brody J, Linton KM, et al. Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/ triple-hit lymphoma: Updated EPCORE NHL-2 data. Clinical Lymphoma, Myeloma and Leukemia. 2023;23(Supplement 1):S431-S2.

38. Vermaat JSP, Brody J, Duras J, Karimi YH, Cheah CY, Darrah JM, et al. Epcoritamab SC + R-Mini-CHOP leads to high complete metabolic response rates in patients with previously untreated diffuse large B-cell lymphoma ineligible for full-dose R-CHOP: First disclosure from arm 8 of the EPCORE NHL-2 trial. Blood. 2023;142(Supplement 1):4457.

39. Brody J, Joergensen JM, Belada D, Costello RT, Trneny M, Vitolo U, et al. Epcoritamab SC + GemOx leads to high complete metabolic response rates in patients with relapsed/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant: Updated results from Epcore NHL-2. Blood. 2023;142(Supplement 1):3092.

40. Abrisqueta P, Falchi L, Phillips TJ, De Vos S, Nijland M, Offner F, et al. Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results. Journal of Clinical Oncology Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO. 2022;40(16 Supplement 1).

41. Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. Journal of Clinical Oncology. 2023;41(12):2238-47.

42. Vose JM, Feldman T, Chamuleau MED, Kim WS, Lugtenburg P, Kim TM, et al. Mitigating the risk of cytokine release syndrome (CRS): Preliminary results from a DLBCL cohort of Epcore NHL-1. Blood. 2023;142(Supplement 1):1729.

43. Patel K, Riedell PA, Tilly H, Ahmed S, Michot JM, Ghesquieres H, et al. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin's lymphoma: Recommended dose safety/efficacy update and escalation exposure-response analysis. Blood. 2022;140(Supplement 1):9470-2.

44. Song Y, Li L, Qian Z, Zhou K, Fan L, Tan P, et al. GB261, an Fc-function enabled and CD3 affinity de-tuned CD20/CD3 bispecific antibody, demonstrated a highly advantageous safety/efficacy balance in an ongoing first-in-human dose-escalation study in patients with relapsed/refractory non-Hodgkin lymphoma. Blood. 2023;142(Supplement 1):1719.

45. Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, et al. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Advances. 2023;7(20):6055-65.

46. Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, et al. Mosunetuzumab safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Clinical management experience from a pivotal phase I/II trial. Clinical Lymphoma, Myeloma & Leukemia. 2024;24(4):240-53.

47. Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nature Medicine. 2024;30(1):229-39.

52. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. Journal of Clinical Oncology. 2022;40(5):481-91.